SCHEMBL5614218

SCHEMBL5614218

NC(=O)CCCCc1ccccc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 4/20 0.51
PTGER4 P35408 4/20 0.51
PTGER3 P43115 4/20 0.51
PTGER2 P43116 4/20 0.51
KMT2A Q03164 1/20 0.50
DPP4 P27487 1/20 0.48
FOLH1 Q04609 1/20 0.47
BCAT2 O15382 1/20 0.46
FFAR1 O14842 2/20 0.44
FFAR4 Q5NUL3 2/20 0.44
HDAC3 O15379 3/20 0.44
HDAC1 Q13547 3/20 0.44
HDAC2 Q92769 3/20 0.44
HDAC6 Q9UBN7 3/20 0.44
HDAC4 P56524 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27742528 0.98 PTGER1 (0.50) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL6206188 0.89 PTGER4 (0.58) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL28313950 0.88 PTGER1 (0.61) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL28959383 0.86 PTGER1 (0.59) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL11069817 0.86 PTGER1 (0.59) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL28417410 0.86 PTGER1 (0.59) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL16178552 0.86 PTGER1 (0.59) PTGER1PTGER4PTGER3PTGER2KMT2A
Bromide SCHEMBL27464773 0.85 PTGER1 (0.58) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL11038460 0.83 PTGER1 (0.49) PTGER1PTGER4PTGER3PTGER2KMT2A
SCHEMBL6843947 0.82 PTGER4 (0.63) PTGER1PTGER4PTGER3PTGER2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP PTGER1 905/4885PTGER4 1590/4885PTGER3 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.